Show All
2013
Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, Saunthararajah Y, Mulloy JC. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. March;121:e90-e97. 2013.
Bell-Horwath, T. B., Vadukoot, A. K., Li, G.; Thowfeik, S., Wunderlich, M., Mulloy, JC, Merino, E. J. Novel oxidatively activated anticancer agents selectively target acute myeloid leukemia. Bioorganic & Medicinal Chemistry Letters 23:2951–2954, 2013.
Goyama S, Mulloy JC. Making healthy stem cells: the new role of TPO. Cell Stem Cell. Jan 3;12(1):8-9. 2013.
2012
Negrotto S, Ng KP, Jankowska AM, Bodo J, Gopalan B, Guinta K, Mulloy JC, Hsi E, Maciejewski J, Saunthararajah Y. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors. Leukemia, 26(2):244-54, Feb 2012.
Maiques-Diaz A, Chou FS, Wunderlich M, Gómez-López G, Jacinto FV, Rodriguez-Perales S, Larrayoz MJ, Calasanz MJ, Mulloy JC, Cigudosa JC, Alvarez S. Chromatin modifications induced by the AML1/ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs. Leukemia, 26(6):1329-37, Jun 2012.
Li Z, Huang H, Chen P, He M, Li Y, Arnovitz S, Jiang X, He C, Hyjek E, Zhang J, Zhang Z, Elkahloun A, Cao D, Shen C, Wunderlich M, Wang Y, Neilly MB, Jin J, Wei M, Lu J, Valk PJ, Delwel R, Lowenberg B, Le Beau MM, Vardiman J, Mulloy JC, Zeleznik-Le NJ, Liu PP, Zhang J, Chen J. miR-196b directly targets bothHOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia. Nat Commun. 2:688. doi: 10.1038/ncomms1681. Feb 21 2012.
Yoshimi M, Goyama S, Kawazu M, Nakagawa M, Ichikawa M, Imai Y, Kumano K, Asai T, Mulloy JC, Kraft AS, Takahashi T, Shirafuji N, Kurokawa M. Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol. 42(4):1044-50. Apr 2012
Chou FS, Griesinger A, Wunderlich M, Lin S, Link KA, Shrestha M, Goyama S, Mizukawa B, Shen S, Marcucci G, Mulloy JC.The THPO/MPL/Bcl-xL pathway is essential for survival and self-renewal in human pre-leukemia induced by AML1-ETO. Blood,(plenary paper) 120 (4): 2012.
Fang J, Rhyasen G, Bolanos L, Rasch C, Varney M, Wunderlich M, Goyama S, Jansen G, Cloos J, Rigolino C, Cortelezzi A, Mulloy JC, Oliva EN, Cuzzola M, Starczynowski DT. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood, 120 (4): 2012.
Zhang Y, Yan X, Sashida G, Zhao X, Rao Y,Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang QF, Tenen DG, Xiao Z, Marcucci G, Mulloy JC, Grimes HL, Caligiuri MA, Huang G. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. Aug 2 2012; 120(5):1118-29. Epub 2012 Jun 26.
2011
Sipes NS, Feng Y, Guo F, Lee HO, Chou FS, Cheng J, Mulloy J, Zheng Y. Cdc42 regulates extracellular matrix remodeling in three dimensions. . J Biol Chem. ;286(42):36469-77. Oct 21 2011.
Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC, Saunthararajah Y. p53 independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia, Nov;25(11):1739-50, 2011.
Mizukawa B, Wei J, Shrestha M, Wunderlich M, Chou FS, Griesinger A, Harris CE, Kumar AR, Zheng Y, Williams DA, Mulloy JC. Survival Signaling through Rac GTPase Proteins is a potential therapeutic target in MLL-AF9 Leukemia. Blood, 118(19): 5235-5245, 2011.
Goyama S, Mulloy JC. Molecular pathogenesis of Core Binding Factor Leukemia: Current knowledge and Future prospects. Int J Hematol. [Epub ahead of print] May 3, 2011 .
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. [Epub ahead of print]. Aug 3 2011.
Ng KP, Ebrahem Q, Negrotto S, Mahfouz RZ, Link KA, Hu Z, Gu X, Advani A, Kalaycio M, Sobecks R, Sekeres M, Copelan E, Radivoyevitch T, Maciejewski J, Mulloy JC, Saunthararajah Y. Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. [Epub ahead of print]. Jun 24, 2011.
Chou FS, Mulloy JC. The thrombopoietin/MPL pathway in hematopoeisis and leukemogenesis. Journal of Cellular Biochemistry. 112(6):1491-1498, 2011.
Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood. 2011.
2010
Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry R, Carroll M, Mulloy JC. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 24(10):1785-8. 2010.
Alvarez S, Suela J, Valencia A, Fernandez A, Wunderlich M, Agirre X, Prosper F, Martin-Subero JI, Maiques A, Acquadro F, Rodriguez-Perales S, Calasanz M, Roman-Gomez J, Siebert R, Mulloy JC, Cervera JV, Sanz MA, Esteller M, Cigudosa JC. DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia. PLoS ONE. 16;5(8). 2010.
Kamikubo Y, Zhao L, Wunderlich M, Corpora T, Hyde RK, Kundu M, Garrett-Beal L, Compton S, Huang G, Ito Y, Bushweller J, Mulloy JC, Liu PP. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1. Cancer Cell. 17(5):455-68. 2010.
Mulloy JC. Peripheral T cell lymphoma: new model + new insight. J Exp Med. 207:911-913. 2010.
Mia S, Lia Z, Chena P, Hea C, Cao D, Elkahlounc A, Lud J, Pelloso LA, Wunderlich M, Huanga H, Luo RT, Sung M, Hea M, Neillya MB, Zeleznik-Le NJ, Thirman MJ, Mulloy JC, Liu PP, Rowley JD, Chen J. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. PNAS. 107(8):3710-5. 2010.
Mulloy JC, Cancelas J, Filippi MD, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood. 115(5):936-47. 2010.
Link KA, Chou FS, Mulloy JC. Core binding factor at the crossroads: determining the fate of the HSC. Journal of Cellular Physiology. 222(1):50-6. Jan, 2010.
2009
2008
Mulloy JC, Wunderlich M, Zheng Y, Wei J. Transforming human blood stem and progenitor cells: a new way forward in leukemia modeling. Cell Cycle. 7(21): 57-52. 2008.
Wei J, Wunderlich M, Fox C, Alvarez S, Cigudosa JC, Wilhelm JE, Zheng Y, Cancelas JA, Gu Y, Jansen M, DiMartino JF, Mulloy JC. Microenvironment determines lineage fate in a human model of MLL-AF9 leukemia. Cancer Cell. 13(6): 483-495. 2008.
Krejci O, Wunderlich M, Geiger H, Schleimer D, Jansen M, Andreassen PR, Mulloy JC. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood. 111(4): 2190-2199. 2008.
Other Significant Publications
Wunderlich M, Krejci O, Wei J, Mulloy JC. Human CD34+ cells expressing the inv(16) fusion protein exhibit a myelomonocytic phenotype with greatly enhanced proliferative ability. Blood. 108(5)1690-1697. 2006.
Mulloy JC, Jankovic V, Wunderlich M, Delwel R, Cammenga J, Krejci O, Zhao H, Valk PJ, Lowenberg B, Nimer SD. AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion. PNAS. 102(11):4016-21. 2005.
Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MAS, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 102(13)4369-4376. 2003.
Mulloy JC, Cammenga J, MacKenzie K, Moore MAS, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 99(1)15-23. 2002.
